|
WO2021064748A1
|
|
Methods for quantification of carbohydrates
|
|
WO2021048878A1
|
|
N-terminal extension sequence for expression of recombinant therapeutic peptides
|
|
WO2020165920A1
|
|
Multivalent vaccine composition
|
|
WO2020157772A1
|
|
Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
|
|
WO2020152706A1
|
|
Multivalent pneumococcal conjugate vaccine compositions
|
|
WO2020075201A1
|
|
Multivalent pneumococcal polysaccharide-protein conjugate vaccine
|
|
WO2020075197A1
|
|
Inactivated poliomyelitis vaccine composition
|
|
WO2020058963A1
|
|
Purified capsular polysaccharides of streptococcus pneumoniae
|
|
KR20210035242A
|
|
Vaccine formulations containing a preservative system
|
|
KR20200129121A
|
|
Expression of pneumococcal surface protein A (PspA)
|
|
EP3740513A1
|
|
Improved process for the preparation of dalteparin sodium
|
|
AU2018385557A1
|
|
Process for the preparation of low molecular weight heparin
|
|
MX2019012563A
|
|
An improved method for high level production of crm.
|
|
BR112019006278A2
|
|
multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
|
|
US2018327457A1
|
|
Industrially scalable process for recovering biologically active recombinant carrier proteins
|
|
CN107810010A
|
|
Multivalent pneumococcal combined vaccine
|
|
US2019240322A1
|
|
Method for preparation of aluminium phosphate gel for application in vaccine formulations
|
|
AU2016254693A1
|
|
Method for separation of protein and other impurities from microbial capsular polysaccharides
|
|
AU2015348922A1
|
|
Codon optimized polynucleotide for high level expression of CRM197
|
|
US2017198004A1
|
|
Novel semi-synthetic meningococcal conjugate vaccine
|
